Monday, October 12, Johnson & Johnson had temporarily paused its COVID-19 vaccine clinical trial due to an unexplained illness in a study participant.
The pharmaceutical giant was unclear if the patient was administered a placebo or the experimental vaccine, and it’s not remarkable for studies as large as the one Johnson & Johnson are conducting – involving 60,000 patients – to be temporarily paused.
“We have temporarily paused further dosing in all our COVID-19 vaccine candidate clinical trials,” J&J revealed in a statement. “Following our guidelines, the participant’s illness is being reviewed and evaluated.”
J&J did not reveal the nature of the illness that brought its trial to a standstill, noting in a statement: “We must respect this participant’s privacy.”
“We’re also learning more about this participant’s illness, and it’s important to have all the facts before we share additional information,” the statement continued.
It said the “study pause” in giving doses of the vaccine candidate was different from a “regulatory hold” required by health authorities.